ArticleDiagnostic cytopathology2026
Case Report: Pancreatic Paraganglioma Mimicking a Well-Differentiated Neuroendocrine Tumor: The Importance of Cytokeratin Immunohistochemistry.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paragangliomas (PGLs) are uncommon neuroendocrine tumors most commonly found in the head and neck that originate from neural crest cells. Primary pancreatic paraganglioma is exceedingly rare and has largely been described in case reports and small case series. We present the case of a 79-year-old woman with an incidental pancreatic head lesion initially favored to represent a well-differentiated neuroendocrine tumor. Endoscopic ultrasound with rapid on-site cytopathologic evaluation demonstrated neoplastic cells with neuroendocrine features. Further immunohistochemical (IHC) workup demonstrated tumor cells negative for cytokeratins and positive for GATA-3, supporting a diagnosis of paraganglioma over a well-differentiated neuroendocrine tumor. Cytokeratin immunohistochemistry should be employed alongside neuroendocrine markers in the workup of neuroendocrine tumors to avoid misdiagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.